Castalagin Cancer Research Results

Cast, Castalagin: Click to Expand ⟱
Features:

Castalagin — a high-molecular-weight C-glucosidic ellagitannin and dietary polyphenol found in camu camu (Myrciaria dubia), oak (Quercus spp.), chestnut (Castanea sativa), and several other plants. It is best classified with the chemical class ellagitannin / hydrolyzable tannin / polyphenol. No widely established pharmacological abbreviation exists; “castalagin” is preferable to creating an abbreviation. Its molecular formula is C41H26O26 and molecular mass is approximately 934.6 g/mol. Castalagin is the C-1 epimer of vescalagin and is converted by intestinal microbiota through intermediates including castalin and ellagic acid to urolithins. Its most compelling cancer activity is not conventional direct tumor-cell cytotoxicity but microbiome-dependent modulation of antitumor immunity and immune-checkpoint inhibitor response.

Primary mechanisms (ranked):

  1. Direct interaction with selected gut bacteria, particularly Ruminococcus bromii, with enrichment of Ruminococcaceae and other taxa associated with favorable immune-checkpoint inhibitor responses.
  2. Gut-microbiome-dependent enhancement of antitumor immunity, including increased intratumoral CD8+ T-cell activity and an increased CD8+/FOXP3+CD4+ T-cell ratio.
  3. Sensitization or resensitization to anti-PD-1 immune-checkpoint blockade in preclinical resistant tumor models.
  4. Microbiome-dependent remodeling of bile-acid metabolism, including changes in conjugated and secondary bile acids; experimental evidence indicates that bile-acid receptor signaling is mechanistically involved in the antitumor phenotype.
  5. Metabolism to ellagic-acid-derived urolithins, with strong interindividual dependence on gut microbial composition; urolithin production may contribute to systemic metabolic and immunological signaling.
  6. Context-dependent anti-inflammatory activity, including suppression of NF-κB-associated IL-8 and IL-6 signaling in epithelial infection/inflammation models; this is distinct from its principal cancer immunotherapy mechanism.

Bioavailability / PK relevance: Intact castalagin appears to have very low systemic availability and functions predominantly within the gastrointestinal compartment. In mice receiving oral castalagin at doses up to approximately 17 mg/kg/day, intact castalagin was not detectable by HPLC in serum or feces, consistent with rapid transformation and strong interaction with the intestinal microbiota. Its biologically relevant systemic consequences therefore appear to arise mainly from microbiome restructuring and microbial metabolites, particularly urolithins and altered bile-acid profiles, rather than sustained circulating intact castalagin. Interindividual microbiome composition is consequently a major pharmacodynamic determinant.

In-vitro vs systemic exposure relevance: Direct cellular effects observed with purified ellagitannins at micromolar concentrations should not automatically be interpreted as achievable systemic castalagin effects because intact oral castalagin has poor demonstrated systemic exposure. The strongest translationally relevant mechanism is gut-local and microbiome-mediated rather than concentration-driven exposure of tumors to intact castalagin. Importantly, ROS induction, DNA damage, and CHK1-inhibitor sensitization recently reported for castalin should not currently be assigned directly to castalagin.

Clinical evidence status: Preclinical evidence for purified castalagin; early human adjunct evidence for castalagin-containing camu camu. Purified castalagin has demonstrated antitumor and anti-PD-1-resensitizing activity in multiple murine tumor models. Human oncology studies have administered camu camu rather than isolated pharmaceutical castalagin. A completed phase I study of camu camu plus immune-checkpoint therapy in melanoma and NSCLC reported acceptable safety and encouraging preliminary activity, with metabolomic changes including increased urolithins and altered bile acids. Two earlier ICI-refractory melanoma cases also showed durable responses after camu camu was added to nivolumab. A separate phase I renal-cell carcinoma study of camu camu with nivolumab/ipilimumab enrolled 31 patients but was listed as suspended in October 2026 for an administrative DSMC reporting issue after accrual had closed. Castalagin itself is therefore an experimental microbiome-directed immunotherapy adjunct and is not an approved anticancer drug.

Castalagin Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Gut microbiome–Ruminococcus interaction ↔ direct exposure ↑ Ruminococcus bromii and selected Ruminococcaceae Microbiome remodeling Castalagin preferentially associates with the cellular envelope of R. bromii. Its antitumor activity is strongly microbiome-dependent and is lost or markedly altered when the relevant microbial ecosystem is absent.
2 Anti-PD-1 sensitization ↑ immune-mediated tumor control ↑ antitumor immune competence Restoration of checkpoint-inhibitor responsiveness Purified castalagin enhanced anti-PD-1 efficacy and partially overcame resistance transferred by fecal microbiota from ICI-nonresponsive patients in mouse models.
3 CD8 T-cell antitumor immunity ↑ immune pressure ↑ CD8+ memory and effector responses More immunologically active tumor microenvironment Associated with ↑ CD8+/FOXP3+CD4+ ratio, ↑ memory CD8+ T cells, and transcriptional enrichment of antigen-processing and T-cell receptor pathways.
4 Bile-acid signaling ↑ indirect immune-mediated control ↑ altered conjugated and secondary bile-acid signaling Microbiome-metabolite-immune coupling Castalagin changes systemic and intestinal bile-acid profiles. Later preclinical work indicates that disruption of bile-acid receptor signaling can attenuate its antitumor activity, supporting a mechanistic rather than merely correlative role.
5 Urolithin production ↔ direct effect uncertain ↑ microbial production (context-dependent) Generation of bioavailable microbial metabolites Castalagin is metabolized through ellagic-acid-related pathways to urolithins. Production varies substantially between individuals according to microbiome composition and was more frequent in microbiomes from ICI responders in ex-vivo studies.
6 NF-κB inflammatory signaling ↓ (context-dependent) ↓ NF-κB, IL-8 and IL-6 (context-dependent) Anti-inflammatory activity Observed particularly in gastric epithelial and keratinocyte infection models. This pathway should be considered secondary to the microbiome-immunotherapy mechanism in oncology.
7 Direct tumor cytotoxicity ↔ insufficient evidence ↔ Not established as the principal anticancer mechanism High systemic concentrations of intact oral castalagin have not been demonstrated. ROS-driven DNA damage reported for castalin should not be extrapolated directly to castalagin.
8 Clinical Translation Constraint ↔ ↔ Limits direct therapeutic interpretation Very low intact systemic exposure, substantial microbiome-dependent metabolism, heterogeneous urolithin production, absence of isolated-castalagin oncology trials, and current human evidence based primarily on camu camu preparations rather than purified castalagin.


Scientific Papers found: Click to Expand⟱
9143- Cast,    Chestnut (Castanea sativa Mill.) leaf extract and pure castalagin reduce bacterial colonisation and the associated inflammation in gastric organoids and a mouse model of H. pylori infection
- in-vivo, Nor, NA
*Inflam↓, *Bacteria↓, *NF-kB↓, *CXCR2↓, *CXCR3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

CXCR2↓, 1,   CXCR3↓, 1,   Inflam↓, 1,   NF-kB↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 5

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:529  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page